<DOC>
	<DOCNO>NCT00529100</DOCNO>
	<brief_summary>Measure 1 year survival non small cell lung cancer ( NSCLC ) patient treat pemetrexed combination cisplatin radiation .</brief_summary>
	<brief_title>Concurrent Pemetrexed , Cisplatin Radiation Therapy Patients With Stage IIIA/B Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Some requirement study : Patient must least 18 year old . Patient must diagnose nonsmall cell lung cancer . Patient must able visit doctor 's office week . Patient must adequate blood , liver , lung kidney function within requirement study . Female patient childbearing potential must test negative pregnancy time enrollment base serum pregnancy test . Male female patient must agree use reliable method birth control 3 month follow last dose study drug . Patients participate study follow reason : Patient previously chemotherapy . Patient previously thoracic radiation therapy . Patient receive treatment within last 30 day drug receive approval Health Canada indication time study entry . Female patient pregnant breastfeeding . Patient unsuitable participate study opinion investigator . Patient unable unwilling take folic acid , vitamin B12 supplementation , dexamethasone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>